HEADER TRANSCRIPTION 11-APR-12 4EMA TITLE HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH TITLE 2 ROSIGLITAZONE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN, UNP RESIDUES 235-505; COMPND 5 SYNONYM: PPAR-GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS NUCLEAR RECEPTOR, RETINOIC ACID RECEPTOR, NUCLEUS, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR M.V.LIBERATO,A.S.NASCIMENTO,I.POLIKARPOV REVDAT 2 28-FEB-24 4EMA 1 REMARK SEQADV REVDAT 1 06-MAR-13 4EMA 0 JRNL AUTH M.V.LIBERATO,A.S.NASCIMENTO,S.D.AYERS,J.Z.LIN,A.CVORO, JRNL AUTH 2 R.L.SILVEIRA,L.MARTINEZ,P.C.SOUZA,D.SAIDEMBERG,T.DENG, JRNL AUTH 3 A.A.AMATO,M.TOGASHI,W.A.HSUEH,K.PHILLIPS,M.S.PALMA, JRNL AUTH 4 F.A.NEVES,M.S.SKAF,P.WEBB,I.POLIKARPOV JRNL TITL MEDIUM CHAIN FATTY ACIDS ARE SELECTIVE PEROXISOME JRNL TITL 2 PROLIFERATOR ACTIVATED RECEPTOR (PPAR) GAMMA ACTIVATORS AND JRNL TITL 3 PAN-PPAR PARTIAL AGONISTS JRNL REF PLOS ONE V. 7 36297 2012 JRNL REFN ESSN 1932-6203 JRNL PMID 22649490 JRNL DOI 10.1371/JOURNAL.PONE.0036297 REMARK 2 REMARK 2 RESOLUTION. 2.55 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.55 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.89 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 3 NUMBER OF REFLECTIONS : 20835 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.182 REMARK 3 R VALUE (WORKING SET) : 0.180 REMARK 3 FREE R VALUE : 0.225 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.140 REMARK 3 FREE R VALUE TEST SET COUNT : 1071 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 28.8900 - 5.0825 1.00 2571 147 0.1833 0.1760 REMARK 3 2 5.0825 - 4.0377 1.00 2519 153 0.1420 0.1908 REMARK 3 3 4.0377 - 3.5283 1.00 2521 122 0.1570 0.2242 REMARK 3 4 3.5283 - 3.2062 1.00 2501 131 0.1810 0.2625 REMARK 3 5 3.2062 - 2.9766 1.00 2519 124 0.2041 0.2939 REMARK 3 6 2.9766 - 2.8013 0.99 2443 149 0.2151 0.2716 REMARK 3 7 2.8013 - 2.6611 0.97 2412 120 0.2294 0.3391 REMARK 3 8 2.6611 - 2.5450 0.91 2278 125 0.2590 0.2993 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.37 REMARK 3 B_SOL : 71.04 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.360 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 24.400 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -7.64300 REMARK 3 B22 (A**2) : 3.05240 REMARK 3 B33 (A**2) : 4.59060 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -4.43360 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.011 4090 REMARK 3 ANGLE : 1.583 5510 REMARK 3 CHIRALITY : 0.104 637 REMARK 3 PLANARITY : 0.006 699 REMARK 3 DIHEDRAL : 21.302 1539 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 3 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: ( CHAIN A AND ( RESID 207:477 OR RESID 601:601 ) ) REMARK 3 ORIGIN FOR THE GROUP (A): 20.4168 -0.0758 40.7091 REMARK 3 T TENSOR REMARK 3 T11: 0.3046 T22: 0.1750 REMARK 3 T33: 0.1940 T12: 0.0291 REMARK 3 T13: 0.0384 T23: 0.0077 REMARK 3 L TENSOR REMARK 3 L11: 2.3964 L22: 1.0113 REMARK 3 L33: 1.0361 L12: -0.4869 REMARK 3 L13: -0.2429 L23: -0.4972 REMARK 3 S TENSOR REMARK 3 S11: -0.0407 S12: -0.0006 S13: -0.1958 REMARK 3 S21: 0.1040 S22: 0.1100 S23: 0.1105 REMARK 3 S31: -0.0655 S32: -0.0969 S33: -0.0750 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: ( CHAIN B AND RESID 207:474 ) REMARK 3 ORIGIN FOR THE GROUP (A): 4.6505 -20.7960 23.5668 REMARK 3 T TENSOR REMARK 3 T11: 0.3359 T22: 0.2522 REMARK 3 T33: 0.1377 T12: 0.0102 REMARK 3 T13: 0.0839 T23: 0.0099 REMARK 3 L TENSOR REMARK 3 L11: 2.6079 L22: 1.3858 REMARK 3 L33: 0.1739 L12: -0.5525 REMARK 3 L13: -1.0267 L23: 0.2201 REMARK 3 S TENSOR REMARK 3 S11: 0.2378 S12: 0.5052 S13: -0.0329 REMARK 3 S21: -0.0603 S22: -0.1501 S23: -0.0778 REMARK 3 S31: 0.0312 S32: -0.0941 S33: -0.0771 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: ( CHAIN A AND RESID 701:743 ) OR ( CHAIN B AND RESID REMARK 3 501:536 ) REMARK 3 ORIGIN FOR THE GROUP (A): 16.5242 -12.1320 34.5288 REMARK 3 T TENSOR REMARK 3 T11: 0.4329 T22: 0.4318 REMARK 3 T33: 0.4032 T12: 0.0253 REMARK 3 T13: 0.0478 T23: -0.0218 REMARK 3 L TENSOR REMARK 3 L11: 0.1138 L22: 0.3339 REMARK 3 L33: 0.0275 L12: 0.1532 REMARK 3 L13: 0.1743 L23: 0.1786 REMARK 3 S TENSOR REMARK 3 S11: 0.0863 S12: 0.0025 S13: -0.0577 REMARK 3 S21: -0.0847 S22: -0.1646 S23: -0.0697 REMARK 3 S31: 0.0552 S32: -0.0258 S33: 0.0300 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4EMA COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 03-MAY-12. REMARK 100 THE DEPOSITION ID IS D_1000071796. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-MAY-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : LNLS REMARK 200 BEAMLINE : W01B-MX2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.46 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 225 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20835 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.540 REMARK 200 RESOLUTION RANGE LOW (A) : 28.890 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.54 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.64 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.58 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1M TRIS-HCL, 0.9M SODIUM CITRATE, PH REMARK 280 7.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 45.25550 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.97900 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 45.25550 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.97900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2570 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 24280 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -17.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 2 1.000000 0.000000 0.000000 45.25550 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 30.97900 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 203 REMARK 465 SER A 204 REMARK 465 HIS A 205 REMARK 465 MET A 206 REMARK 465 LYS A 261 REMARK 465 ILE A 262 REMARK 465 LYS A 263 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 LYS A 275 REMARK 465 GLY B 203 REMARK 465 SER B 204 REMARK 465 HIS B 205 REMARK 465 MET B 206 REMARK 465 LYS B 240 REMARK 465 THR B 241 REMARK 465 THR B 242 REMARK 465 LYS B 261 REMARK 465 ILE B 262 REMARK 465 LYS B 263 REMARK 465 PHE B 264 REMARK 465 LYS B 265 REMARK 465 HIS B 266 REMARK 465 ILE B 267 REMARK 465 THR B 268 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 LYS B 275 REMARK 465 ILE B 456 REMARK 465 LYS B 457 REMARK 465 LYS B 458 REMARK 465 THR B 459 REMARK 465 GLU B 460 REMARK 465 THR B 461 REMARK 465 ASP B 475 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 LYS A 457 CD REMARK 480 GLU B 369 CD REMARK 480 GLU B 427 CB CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 246 C - N - CA ANGL. DEV. = 10.2 DEGREES REMARK 500 PRO A 398 C - N - CA ANGL. DEV. = 9.9 DEGREES REMARK 500 GLU B 207 CB - CA - C ANGL. DEV. = 13.6 DEGREES REMARK 500 GLY B 239 N - CA - C ANGL. DEV. = -17.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 4.67 -68.90 REMARK 500 THR A 242 -65.92 -95.69 REMARK 500 GLU A 259 58.96 -154.99 REMARK 500 LYS A 354 -7.40 -58.39 REMARK 500 LYS A 358 134.29 -38.18 REMARK 500 LEU A 401 -61.59 -91.31 REMARK 500 MET A 463 81.45 -64.13 REMARK 500 THR B 238 -56.99 -123.91 REMARK 500 LYS B 336 -35.14 -33.32 REMARK 500 SER B 355 31.48 -84.49 REMARK 500 ARG B 357 107.62 -51.74 REMARK 500 LYS B 358 139.05 -39.80 REMARK 500 LEU B 393 49.03 -84.14 REMARK 500 MET B 463 -10.08 77.57 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASP B 462 MET B 463 128.97 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BRL A 601 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1ZEO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN REMARK 900 COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR REMARK 900 ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 3GWX RELATED DB: PDB REMARK 900 MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR- REMARK 900 ACTIVATED RECEPTORS REMARK 900 RELATED ID: 2VV1 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA REMARK 900 RELATED ID: 3DZU RELATED DB: PDB REMARK 900 INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND REMARK 900 WITH BVT.13, 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE REMARK 900 RELATED ID: 3DZY RELATED DB: PDB REMARK 900 INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND REMARK 900 WITH ROSIGLITAZONE, 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE REMARK 900 RELATED ID: 4EM9 RELATED DB: PDB DBREF 4EMA A 207 477 UNP P37231 PPARG_HUMAN 235 505 DBREF 4EMA B 207 477 UNP P37231 PPARG_HUMAN 235 505 SEQADV 4EMA GLY A 203 UNP P37231 EXPRESSION TAG SEQADV 4EMA SER A 204 UNP P37231 EXPRESSION TAG SEQADV 4EMA HIS A 205 UNP P37231 EXPRESSION TAG SEQADV 4EMA MET A 206 UNP P37231 EXPRESSION TAG SEQADV 4EMA GLY B 203 UNP P37231 EXPRESSION TAG SEQADV 4EMA SER B 204 UNP P37231 EXPRESSION TAG SEQADV 4EMA HIS B 205 UNP P37231 EXPRESSION TAG SEQADV 4EMA MET B 206 UNP P37231 EXPRESSION TAG SEQRES 1 A 275 GLY SER HIS MET GLU SER ALA ASP LEU ARG ALA LEU ALA SEQRES 2 A 275 LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU SEQRES 3 A 275 THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR SEQRES 4 A 275 THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER SEQRES 5 A 275 LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE SEQRES 6 A 275 THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG SEQRES 7 A 275 ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL SEQRES 8 A 275 GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE SEQRES 9 A 275 VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS SEQRES 10 A 275 TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER SEQRES 11 A 275 LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN SEQRES 12 A 275 GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS SEQRES 13 A 275 PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA SEQRES 14 A 275 VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU SEQRES 15 A 275 ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG SEQRES 16 A 275 PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN SEQRES 17 A 275 ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU SEQRES 18 A 275 ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU SEQRES 19 A 275 GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS SEQRES 20 A 275 VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP SEQRES 21 A 275 MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP SEQRES 22 A 275 LEU TYR SEQRES 1 B 275 GLY SER HIS MET GLU SER ALA ASP LEU ARG ALA LEU ALA SEQRES 2 B 275 LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU SEQRES 3 B 275 THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR SEQRES 4 B 275 THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER SEQRES 5 B 275 LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE SEQRES 6 B 275 THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG SEQRES 7 B 275 ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL SEQRES 8 B 275 GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE SEQRES 9 B 275 VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS SEQRES 10 B 275 TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER SEQRES 11 B 275 LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN SEQRES 12 B 275 GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS SEQRES 13 B 275 PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA SEQRES 14 B 275 VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU SEQRES 15 B 275 ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG SEQRES 16 B 275 PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN SEQRES 17 B 275 ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU SEQRES 18 B 275 ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU SEQRES 19 B 275 GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS SEQRES 20 B 275 VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP SEQRES 21 B 275 MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP SEQRES 22 B 275 LEU TYR HET BRL A 601 25 HETNAM BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2- HETNAM 2 BRL PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) HETSYN BRL BRL49653; ROSIGLITAZONE FORMUL 3 BRL C18 H19 N3 O3 S FORMUL 4 HOH *79(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 GLY A 258 1 8 HELIX 4 4 VAL A 277 SER A 302 1 26 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 LEU A 333 1 24 HELIX 7 7 ARG A 350 LYS A 354 1 5 HELIX 8 8 PRO A 359 PHE A 363 5 5 HELIX 9 9 MET A 364 ASN A 375 1 12 HELIX 10 10 ALA A 376 GLU A 378 5 3 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 LYS A 458 1 29 HELIX 14 14 HIS A 466 LYS A 474 1 9 HELIX 15 15 SER B 208 PHE B 226 1 19 HELIX 16 16 THR B 229 LEU B 237 1 9 HELIX 17 17 ASP B 251 GLY B 258 1 8 HELIX 18 18 VAL B 277 SER B 302 1 26 HELIX 19 19 GLY B 305 LEU B 309 5 5 HELIX 20 20 ASP B 310 ALA B 331 1 22 HELIX 21 21 SER B 342 GLY B 344 5 3 HELIX 22 22 ARG B 350 SER B 355 1 6 HELIX 23 23 MET B 364 ALA B 376 1 13 HELIX 24 24 ASP B 380 LEU B 393 1 14 HELIX 25 25 ASN B 402 HIS B 425 1 24 HELIX 26 26 GLN B 430 LEU B 452 1 23 HELIX 27 27 HIS B 466 TYR B 473 1 8 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N ILE A 341 O GLY A 346 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 CISPEP 1 LYS A 358 PRO A 359 0 3.23 CISPEP 2 LYS B 358 PRO B 359 0 8.68 CISPEP 3 GLN B 454 VAL B 455 0 -9.79 SITE 1 AC1 9 ILE A 281 GLY A 284 CYS A 285 SER A 289 SITE 2 AC1 9 HIS A 323 TYR A 327 MET A 364 HIS A 449 SITE 3 AC1 9 TYR A 473 CRYST1 90.511 61.958 117.601 90.00 100.70 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011048 0.000000 0.002088 0.00000 SCALE2 0.000000 0.016140 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008654 0.00000